Lone Star Value Management Lowers stake in Dipexium Pharmaceuticals Inc (DPRX)

Dipexium Pharmaceuticals Inc (DPRX) : Lone Star Value Management reduced its stake in Dipexium Pharmaceuticals Inc by 5.24% during the most recent quarter end. The investment management company now holds a total of 217,805 shares of Dipexium Pharmaceuticals Inc which is valued at $2,657,221 after selling 12,036 shares in Dipexium Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Dipexium Pharmaceuticals Inc makes up approximately 5.49% of Lone Star Value Management’s portfolio.

Other Hedge Funds, Including , Broadfin Capital reduced its stake in DPRX by selling 421,204 shares or 90.39% in the most recent quarter. The Hedge Fund company now holds 44,774 shares of DPRX which is valued at $546,243. Dipexium Pharmaceuticals Inc makes up approx 0.05% of Broadfin Capital’s portfolio.Renaissance Technologies boosted its stake in DPRX in the latest quarter, The investment management firm added 9,900 additional shares and now holds a total of 35,800 shares of Dipexium Pharmaceuticals Inc which is valued at $436,760.Timpani Capital Management boosted its stake in DPRX in the latest quarter, The investment management firm added 20,014 additional shares and now holds a total of 64,124 shares of Dipexium Pharmaceuticals Inc which is valued at $782,313. Dipexium Pharmaceuticals Inc makes up approx 0.31% of Timpani Capital Management’s portfolio.First New York Securities Ny boosted its stake in DPRX in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 2,300 shares of Dipexium Pharmaceuticals Inc which is valued at $24,288. Dipexium Pharmaceuticals Inc makes up approx 0.02% of First New York Securities Ny’s portfolio.

Dipexium Pharmaceuticals Inc opened for trading at $12.6069 and hit $13.215 on the upside on Thursday, eventually ending the session at $12.79, with a gain of 0.71% or 0.09 points. The heightened volatility saw the trading volume jump to 1,01,967 shares. Company has a market cap of $133 M.

Dipexium Pharmaceuticals Inc. is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex a topical antibiotic. Locilex is a chemically synthesized 22-amino acid peptide isolated from the skin of the African Clawed Frog. Its mechanism of action kills microbial targets by disrupting the bacterial cell membrane. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). Locilex affects only the area to which it is applied. Locilex has demonstrated statistical non-inferiority to a systemic antibiotic in a clinical study in patients with Mild or Moderate DFI. It has conducted microbiology studies that highlight the sensitivity of resistant bacteria including methicillin-resistant staphylococcour aureour (MRSA) vancomycin-resistant enterococcour (VRE) extended-spectrum b-lactamase (ESBL) and multi-drug resistant (or MDR) bacteria to pexiganan the active pharmaceutical ingredient (API) in Locilex.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Dipexium Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dipexium Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.